Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.

Molecular pharmaceutics - 6 Aug 2018

Liu Chang, Shaurova Tatiana, Shoemaker Suzanne, Petkovich Martin, Hershberger Pamela A, Wu Yun

Abstract excerpt

Mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor ( EGFR) gene drives the development of lung cancer. EGFR tyrosine kinase inhibitors (EGFR TKIs), including erlotinib and afatinib, are initially effective in treating EGFR mutant nonsmall cell lung cancer (NSCLC). However, drug resistance quickly develops due to several mechanisms, including induction of the epithelial-mesenchymal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcitriol
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to Liposomes

Share to Nanoparticles

Share to Vitamin D3 24-Hydroxylase

Source

Identifiers

PMID: 29902012
DOI: 10.1021/acs.molpharmaceut.8b00307

Genes

EGFR
CDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.PMID 29902012Read ↗

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity Read ↗

Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer.Semantic proximity Read ↗

Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.Semantic proximity Read ↗

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancerSemantic proximity Read ↗

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and EGFR tyrosine kinase inhibitor resistance in non-small cell lung carcinomaSemantic proximity Read ↗

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC TreatmentSemantic proximity Read ↗

Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and NeckSemantic proximity Read ↗

Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations.Semantic proximity Read ↗

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.Semantic proximity Read ↗

CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancerSemantic proximity Read ↗

Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung CancerSemantic proximity Read ↗

Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.